Ocean Biomedical, Inc. (OCEAW)
USD 0.03
(-8.31%)
USD 0.03
(-8.31%)
| Breakdown | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 2.48 Million | 62.34 Million | 1.65 Million | 232 Thousand |
| Selling, General and Administrative Expenses | 2.48 Million | 28.41 Million | 1.6 Million | 197 Thousand |
| Research and Development Expenses | - | 33.93 Million | 49 Thousand | 35 Thousand |
| Other Expenses | - | 1000.00 | -1000.00 | - |
| Cost and Expenses | 2.48 Million | 62.34 Million | 1.65 Million | 232 Thousand |
| Operating Income | -2.48 Million | -62.34 Million | -1.65 Million | -232 Thousand |
| Interest Expense | 691.00 | - | - | - |
| Income Tax Expense | - | -236.55 Thousand | -206.29 Thousand | -171.86 Thousand |
| Earnings before Tax | -958.43 Thousand | -62.34 Million | -1.65 Million | -232 Thousand |
| Net Income | 565.47 Thousand | -62.34 Million | -1.65 Million | -232 Thousand |
| Earnings Per Share Basic | -0.03 | -4.71 | -0.08 | -0.01 |
| Earnings Per Share Diluted | -0.03 | -4.71 | -0.08 | -0.01 |
| Weighted Average Shares Outstanding | 36.49 Million | 13.22 Million | 20.2 Million | 20.2 Million |
| Weighted Average Shares Outstanding (Diluted) | 36.49 Million | 13.22 Million | 20.2 Million | 20.2 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -957.73 Thousand | -564.11 Thousand | -1.65 Million | -232 Thousand |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 2.65 Million | 2.68 Million | 5.22 Million | 614.17 Thousand | 2.48 Million | 1.36 Million |
| Selling, General and Administrative Expenses | 2.35 Million | 2.65 Million | 4.83 Million | 614.17 Thousand | - | 1.36 Million |
| Research and Development Expenses | 305 Thousand | 28 Thousand | 393 Thousand | - | - | 1.85 Million |
| Other Expenses | -3000.00 | -1000.00 | -12.67 Million | - | 2.48 Million | 1000.00 |
| Cost and Expenses | 2.65 Million | 2.68 Million | 5.22 Million | 614.17 Thousand | 2.48 Million | 1.36 Million |
| Operating Income | -2.65 Million | -2.68 Million | -5.22 Million | -614.18 Thousand | -2.48 Million | -1.36 Million |
| Interest Expense | 293 Thousand | 668 Thousand | 1.54 Million | -125.3 Thousand | 691.00 | 61 Thousand |
| Income Tax Expense | 39.58 Thousand | 668 Thousand | 60.63 Million | -54.88 Thousand | -1.52 Million | -27.08 Thousand |
| Earnings before Tax | -14.08 Million | -13.02 Million | -67.4 Million | 410.05 Thousand | -958.43 Thousand | -1.01 Million |
| Net Income | -14.08 Million | -13.02 Million | -128.03 Million | 410.05 Thousand | 565.47 Thousand | -1.01 Million |
| Earnings Per Share Basic | -0.53 | -0.49 | -5.16 | 0.03 | - | -0.08 |
| Earnings Per Share Diluted | -0.53 | -0.49 | -5.16 | 0.03 | - | -0.08 |
| Weighted Average Shares Outstanding | 26.6 Million | 26.46 Million | 24.82 Million | 13.22 Million | 13.22 Million | 13.22 Million |
| Weighted Average Shares Outstanding (Diluted) | 26.6 Million | 26.46 Million | 24.82 Million | 13.22 Million | 13.22 Million | 13.22 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -2.65 Million | -2.68 Million | -17.9 Million | -614.18 Thousand | - | -1.36 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
CYIENT
ROOPAIND
6222
OWLI
BBOX
URGN